(April 25, 2016) New findings published online this month in Obstetrics and Gynecology suggest that hormone therapy (HT) can be used safely to manage menopausal symptoms in women who have undergone treatment for nonserous epithelial ovarian cancer. The study showed no reduction in overall survival with HT use in the entire study population, and it appears to positively influence disease-free survival among younger women.
“The use of HT to treat these symptoms can significantly improve the quality of life of cancer survivors. According to the results of our study, combined with the evidence in the literature, HT may be considered in survivors of nonserous epithelial ovarian cancer who experience menopausal symptoms shortly after treatment,” writes Laura Power, MD, from the Department of Obstetrics, the Department of Gynecology and Reproductive Sciences, and the Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Canada.
Read more about this hormone therapy study on Medscape; and read the abstract in Obstetrics and Gynecology.
